Azalea grew out of collaborative research conducted at the Innovative Genomics Institute in Jennifer Doudna’s lab and in Justin Eyquem’s lab as part of the Gladstone-UCSF Institute of Genomic Immunology. @j-eyquem.bsky.social @innovativegenomics.bsky.social

Genomic medicine has transformed lives through ex vivo cell therapies, now it’s time to make it scalable. Today we unveil Azalea Therapeutics, making in vivo genomic medicine a reality without compromising precision or specificity, starting with T cells!

Exciting collaboration combining multiplex epigenetic reprogramming and site-specific payload integration!

The Weill Cancer Hub is fostering groundbreaking @ucsanfrancisco.bsky.social - @stanford-cancer.bsky.social collaborations to develop transformative cancer therapies. I’m grateful to co-lead one of the selected teams with @mfgrp.bsky.social to advance next-generation in vivo CAR T cell therapy!

Backed by a $100M gift from Joan and Sandy Weill, UCSF and @stanfordmedicine.bsky.social @stanford-cancer.bsky.social are launching Weill Cancer Hub West, a $200M initiative in team science to accelerate cancer research and improve care over the next decade. tiny.ucsf.edu/rZIspe

Excited to share our latest work, now out in @NatureBiotech ! We introduce SEED-Selection, a powerful method that enables high-efficiency enrichment of T cells edited at multiple loci in a single step 🧵👇 www.nature.com/articles/s41...

🚨New paper alert! 🚨 Our latest work in @cp-immunity.bsky.social shows that Ark313, an evolved AAV variant enables in vivo genetic engineering of murine T cells! 🧵👇 sciencedirect.com/science/arti...

Wonderful to see the #immunology community growing here. The first starter pack is full (they cap at 150), so I created a second one. Let me know if you'd like to be added go.bsky.app/PY5tCas go.bsky.app/FmERUoD